Drug development company, Therapeutics has appointed Thomas Hecht as chairman of its board. He will support the company in establishing proof-of-concept for its propriety HTI vaccine as well as building an experienced management team.
UK-based Atlas Genetics, the point-of-care (POC) testing company for family health, has appointed Jeffrey R. Luber as CEO. He replaces John Clarkson, who becomes executive chairman; the current chairman, Neil Butler, will remain with the company as a non-executive director. Luber has broad experience of the life sciences industry, having held multiple leadership roles in both public and private companies.
Concept Life Sciences, the integrated drug discovery, development and analytical services company, has appointed Marc Princivalle as group head of toxicology, to support the growth of the company’s integrated discovery and development services. Princivalle has over 16 years’ experience in toxicology, with expertise in peptides, small molecule and monoclonal antibodies for various indications as well cross-industry experience.
Smith & Nephew, the global medical technology business, has announced that Olivier Bohuon will retire as CEO by the end of 2018.
International clinical diagnostics company, Novacyt has appointed Paul Eros as commercial director of Primerdesign. The appointment completes the company’s investment in its senior commercial leadership team with Ruth Powell as managing director of the NovaPrep and Phil Sefton as managing director of Lab21 Products. Eros has over 30 years’ experience in molecular diagnostics, including strategic global marketing, sales and product management.
Plymouth Science Park has appointed Ian McFadzen has CEO. He moves from the University of Plymouth where he was commercial director of the Marine Innovation Centre. A former research biologist, McFadzen has spent the past 10 years at the university, and has worked on collaborative R&D programmes across Europe, North America and South East Asia. In addition, Michael LeGoff, founder and CEO of Plessey, becomes chairman of the board, taking over from John Acornley, who was serving as interim.
Antony Odell is stepping down as CEO of Tissue Regenix and from the company’s board. Steve Couldwell takes over as CEO, moving from Global Sanofi Biosurgery, where he was COO. John Samuel, non-executive chairman has assumed the role of executive chairman for an interim period.
UK-based cleanroom and laboratory design and construction specialist, Boulting Environmental Services (BES) has appointed Gavin Statham as business development director. Previously senior project manager for systems integration at Olympus Keymed, Statham is expected to develop the BES brand as part of the company’s growth strategy.
US-based hVIVO, a specialty biopharma company with discovery and clinical development capabilities, has appointed Trevor Phillips as executive chairman, succeeding current non-executive chairman, Jaime Ellertson who remains on the board as a non-executive director. Phillips will work closely with the company’s CEO Kym Denny, to drive the business forward.
Medical diagnostics company Mologic, headquartered in Bedfordshire UK, has appointed Mitch Brooker as general manager. The new role has been created to build on Mologic’s current reputation as an R&D provider, and to increase its full-service offering. Brooker has 18 years of experience in medical devices, primarily in POC and cancer diagnostics.
The privately owned Norwegian biopharmaceutical company, Zelluna Immunotherapy has appointed of Miguel Forte as CEO. Forte has commercial experience in regenerative medicine, cell therapy, and in medical and regulatory affairs industries. He is also currently CCO and chair of the commercialisation committee for the International Society of Cellular Therapy. The company specialises in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need.
Bryan Griffen has been appointed director of industry services at PMMI, the US Association for Packaging and Processing Technologies. Griffen comes to PMMI after 19 years at food and beverage company Nestle.
BioBeat’s annual report, 50 movers and shakers in bioBusiness 2017, has recognised Lindy Durrant of cancer-focused immunotherapy developer Scancell, as an outstanding women entrepreneur and business leader in the healthcare sector. Durrant has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies and cancer vaccines.
Madeleine Jones, deputy operations manager at the nuclear fuel plant at Sellafield, has received the Karen Burt Award from the Women’s Engineering Society (WES). She was nominated for the award, which was established to encourage more women to become chartered engineer status as early in their career as possible, by the Institution of Chemical Engineers (IChemE).
NCH Europe, global provider of biological wastewater treatment, has appointed Gregor Gorenc as its technical applications manager for its wastewater innovation platform. Since joining the company in 2011, he has been involved in the development of over 30 new formulations, managing new product development and running field trials in several countries.
UK-based process engineering company, BPE has appointed John Aspinall as a senior project manager. In addition, graduate chemical engineer Sam Fass and graduate electrical engineer Antonios Gourdouparis have been taken on as part of the company’s five-year growth strategy.